CClinicalTrials.gg
Sign In
Status unknownNCT05590091Updated Oct 21, 2022

Study on Intelligent Nutrition Support Therapy for Hematopoietic Stem Cell Transplantation Recipients

An interventional study of Parenteral nutrition;Enteral nutrition in Nutrition Aspect of Cancer and Stem Cell Transplant Complications, sponsored by Hebei Yanda Ludaopei Hospital. Status unknown. Open to participants aged 12 Years to 55 Years. Per ClinicalTrials.gov, last updated 2022-10-21.

Sponsored by Hebei Yanda Ludaopei Hospital · Not applicable, Interventional, and Other

The sponsor has not verified this record recently (last verified Oct 2022), so the status shown — last known as Not yet recruiting — may be out of date.
Phase
Not applicable
Study type
Interventional
Enrollment
106
Allocation
Randomized
Ages
12 Years to 55 Years
Sex
All
01

Study summary

The use of high-dose radiotherapy, chemotherapy and preventive antibiotics in the preconditioning regimen before allogeneic hematopoietic stem cell transplantation can easily lead to damage to the gastrointestinal mucosa, resulting in malnutrition, and even progression to cachexia, which directly leads to multiple organ failure; The damage of the intestinal mucosal barrier, secondary to the translocation of intestinal-derived bacteria, leads to bloodstream infection and lung infection (drug-resistant Enterobacteriaceae, especially carbapenem-resistant Enterobacteriaceae infection) is one of the challenges faced in clinical treatment. A major problem that affects the long-term survival rate of patients. Nutrition therapy based on the support and guidance of the intelligent nutrition management system aims to improve the adherence and compliance rate of patients with nutritional support therapy through scientific and accurate monitoring and intervention, thereby improving the nutritional status of patients and improving the tolerance of patients to radiotherapy and chemotherapy， and reduce the incidence of adverse reactions. At the same time, it is expected that nutritional support therapy will protect the integrity of the intestinal mucosal barrier of patients, reduce the incidence of enterobacteriaceae bacterial infections (mainly drug-resistant Klebsiella pneumoniae and Escherichia coli infections), and ultimately improve the long-term survival rate. Purpose.

This trial objects are patients who are going to undergo allogeneic hematopoietic stem cell transplantation, and explores the use of intelligent nutrition management system for data support to reduce the incidence and severity of malnutrition, especially cachexia, and to help reduce the incidence and severity of Enterobacteriaceae bacterial infections. It can reduce the incidence of acute intestinal GVHD and ultimately improve the long-term survival rate and quality of life of patients.

Read the detailed description
  1. Background The use of high-dose radiotherapy, chemotherapy and preventive antibiotics in the preconditioning regimen before allogeneic hematopoietic stem cell transplantation can easily lead to damage to the gastrointestinal mucosa, resulting in malnutrition, and even progression to cachexia, which directly leads to multiple organ failure; The damage of the intestinal mucosal barrier, secondary to the translocation of intestinal-derived bacteria, leads to bloodstream infection and lung infection (drug-resistant Enterobacteriaceae, especially carbapenem-resistant Enterobacteriaceae infection) is one of the challenges faced in clinical treatment. A major problem that affects the long-term survival rate of patients. Nutrition therapy based on the support and guidance of the intelligent nutrition management system aims to improve the compliance and compliance rate of patients with nutritional support therapy through scientific and accurate monitoring and intervention, thereby improving the nutritional status of patients and improving the tolerance of patients to radiotherapy and chemotherapy. Reduce the incidence of adverse reactions. At the same time, it is hoped that nutritional support therapy will protect the integrity of the intestinal mucosal barrier of patients, reduce the incidence of Enterobacteriaceae bacterial infections (mainly drug-resistant Klebsiella pneumoniae and Escherichia coli infections), and ultimately improve the long-term survival rate.
  2. Purposes To investigate the effect of continuous nutritional therapy on the nutritional status of allogeneic HSCT recipients based on an intelligent nutritional management system, and to reduce the incidence of malnutrition during peri-transplantation.
  3. Conditions to be met to participate in a study/trial Inclusion criteria: 1. Age 12-55 years old; 2. Patients who are about to receive allo-HSCT (1-2 weeks before pretreatment) ; 3. No serious medical and surgical complications, no mental and psychological diseases; 4. . Those who voluntarily participate in the study and sign the informed consent in writing. 4. No serious allergic diseases, especially those with milk protein allergy; Exclusion criteria: 1. Physical discomfort during the test; 2. Complicated with severe infection or other serious underlying diseases, and the duration of hemodynamic instability is ≥5 days; 3. Severe liver and kidney dysfunction and coagulation disorders persist Time ≥ 5 days; 4. Intractable cachexia phase/refractory phase: tumor continues to progress, no response to treatment; catabolism is active, and body weight continues to lose weight that cannot be corrected 5. Being unable to understand or comply with the research protocol due to clinical symptoms of brain dysfunction or severe mental illness; 6. drug abuse, medical, psychological or social conditions that may interfere with the subject's participation in the research or the evaluation of the research results; 7. Those who cannot be followed up as scheduled; 8. The investigator believes that the subject has any clinical or laboratory abnormalities or compliance problems that are not suitable for participation in this clinical study.
  4. Number of trail subjects This clinical trial is a randomized controlled trial, and plans to recruit a total of 106 subjects, with 53 subjects in the experimental group and 53 in the control group .
  5. Research/Trial Process This study is a randomized controlled clinical trial. After signing the informed consent, the subjects who meet the inclusion and exclusion criteria will be randomly assigned to the experimental group and the control group at a ratio of 1:1. The control group only receives conventional treatment, while the experimental group receives precise nutritional intervention with the assistance of an intelligent nutrition system. The intervention period of the experimental group will be 100 days after being enrolled and receiving the transplantation. The patients in the control group and experimental group will be followed up at -5d before transplantation and +6d, +30d, +60d, +100d, +180d, and +360d after transplantation. .

Randomized trial : The grouping is randomly performed by the computer, so that the bias caused by the grouping can be avoided. Each subject had a 50% chance of being assigned to both the experimental group and the control group.

02

Conditions studied

  • Nutrition Aspect of Cancer
  • Stem Cell Transplant Complications

Keywords

  • HSCT
  • Nutrition therapy
  • Intestinal graft-versus-host disease
03

In context

Lead sponsor

Hebei Yanda Ludaopei Hospital is the lead sponsor of 15 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
12 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • Age 12-55 years old;
  • Patients who are about to receive allo-HSCT (1-2 weeks before pretreatment);
  • No serious medical and surgical complications, no mental and psychological diseases;
  • Those who voluntarily participate in the research and sign the informed consent.
  • No serious allergic diseases, especially those with milk protein allergy

Exclusion criteria

Exclusion Criteria:

  • Feeling unwell during the test;
  • Combined with severe infection or other serious underlying diseases, the duration of hemodynamic instability is ≥5 days;
  • Severe liver and kidney dysfunction and coagulation disorder for ≥5 days;
  • Intractable cachexia/refractory stage: the tumor continues to progress and does not respond to treatment; the catabolism is active, and the body weight continues to lose weight that cannot be corrected
  • Clinical symptoms of brain dysfunction or severe mental illness, unable to understand or comply with the research protocol;
  • Drug abuse, medical, psychological or social conditions that may interfere with the subject's participation in the research or the evaluation of the research results;
  • Those who cannot be followed up as scheduled;
  • The investigator believes that the subjects have any clinical or laboratory abnormalities or compliance problems and are not suitable to participate in this clinical study
05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
106 participants (estimated)

Study arms

  • Experimental
    Experimental group

    roup A were given precise dietary guidance and enteral and parenteral nutrition support treatment using only nutrition software. It is recommended that the precise recommended time covers the start of enrollment until 100 days after transplantation

    Other: Parenteral nutrition;Enteral nutrition

  • No intervention
    The control group

    Group B patients were given the routine nutritional support treatment plan commonly used in clinics. Patients in both groups were monitored and followed up at -5d before transplantation and at +6d, +30d, +60d, +100d, +180d, and +360d after transplantation.

Interventions

  • OtherParenteral nutrition;Enteral nutrition

    The intelligent nutrition management system was used to carry out standardized nutrition management of patients after hematopoietic stem cell transplantation

06

What researchers measure

Primary outcomes

  1. Number of participants who fell sick and vomit at certain checkpoint of transplantation

    Use the Clinical Study Case Reports sheet to record whether each participant developed symptoms of sick and vomit and statistics the number of participants who developed these symptoms

    Time frame: 5 days before transplantation

  2. Number of participants who fell sick and vomit at certain checkpoint of transplantation

    Use the Clinical Study Case Reports sheet to record whether each participant developed symptoms of sick and vomit and statistics the number of participants who developed these symptoms

    Time frame: 6 days after transplantation

  3. Number of participants who fell sick and vomit at certain checkpoint of transplantation

    Use the Clinical Study Case Reports sheet to record whether each participant developed symptoms of sick and vomit and statistics the number of participants who developed these symptoms

    Time frame: 30 days after transplantation

  4. Number of participants who fell sick and vomit at certain checkpoint of transplantation

    Use the Clinical Study Case Reports sheet to record whether each participant developed symptoms of sick and vomit and statistics the number of participants who developed these symptoms

    Time frame: 60 days after transplantation

  5. Number of participants who fell sick and vomit at certain checkpoint of transplantation

    Use the Clinical Study Case Reports sheet to record whether each participant developed symptoms of sick and vomit and statistics the number of participants who developed these symptoms

    Time frame: 100 days after transplantation

  6. Number of participants who fell sick and vomit at certain checkpoint of transplantation

    Use the Clinical Study Case Reports sheet to record whether each participant developed symptoms of sick and vomit and statistics the number of participants who developed these symptoms

    Time frame: 180 days after transplantation

  7. Number of participants who fell sick and vomit at certain checkpoint of transplantation

    Use the Clinical Study Case Reports sheet to record whether each participant developed symptoms of sick and vomit and statistics the number of participants who developed these symptoms

    Time frame: 360 days after transplantation

  8. Number of participants who fell constipate at certain checkpoint of transplantation

    Use the Clinical Study Case Reports sheet to record whether each participant developed symptoms of constipate and statistics the number of participants who developed these symptoms

    Time frame: 5 days before transplantation

  9. Number of participants who fell constipate at certain checkpoint of transplantation

    Use the Clinical Study Case Reports sheet to record whether each participant developed symptoms of constipate and statistics the number of participants who developed these symptoms

    Time frame: 6 days after transplantation

  10. Number of participants who fell constipate at certain checkpoint of transplantation

    Use the Clinical Study Case Reports sheet to record whether each participant developed symptoms of constipate and statistics the number of participants who developed these symptoms

    Time frame: 30 days after transplantation

  11. Number of participants who fell constipate at certain checkpoint of transplantation

    Use the Clinical Study Case Reports sheet to record whether each participant developed symptoms of constipate and statistics the number of participants who developed these symptoms

    Time frame: 60 days after transplantation

  12. Number of participants who fell constipate at certain checkpoint of transplantation

    Use the Clinical Study Case Reports sheet to record whether each participant developed symptoms of constipate and statistics the number of participants who developed these symptoms

    Time frame: 100 days after transplantation

  13. Number of participants who fell constipate at certain checkpoint of transplantation

    Use the Clinical Study Case Reports sheet to record whether each participant developed symptoms of constipate and statistics the number of participants who developed these symptoms

    Time frame: 180 days after transplantation

  14. Number of participants who fell constipate at certain checkpoint of transplantation

    Use the Clinical Study Case Reports sheet to record whether each participant developed symptoms of constipate and statistics the number of participants who developed these symptoms

    Time frame: 360 days after transplantation

  15. Number of participants who fell difficulty urinating at certain checkpoint of transplantation

    Use the Clinical Study Case Reports sheet to record whether each participant developed symptoms of difficulty urinating and statistics the number of participants who developed these symptoms

    Time frame: 5 days before transplantation

  16. Number of participants who fell difficulty urinating at certain checkpoint of transplantation

    Use the Clinical Study Case Reports sheet to record whether each participant developed symptoms of difficulty urinating and statistics the number of participants who developed these symptoms

    Time frame: 6 days after transplantation

  17. Number of participants who fell difficulty urinating at certain checkpoint of transplantation

    Use the Clinical Study Case Reports sheet to record whether each participant developed symptoms of difficulty urinating and statistics the number of participants who developed these symptoms

    Time frame: 30 days after transplantation

  18. Number of participants who fell difficulty urinating at certain checkpoint of transplantation

    Use the Clinical Study Case Reports sheet to record whether each participant developed symptoms of difficulty urinating and statistics the number of participants who developed these symptoms

    Time frame: 60 days after transplantation

  19. Number of participants who fell difficulty urinating at certain checkpoint of transplantation

    Use the Clinical Study Case Reports sheet to record whether each participant developed symptoms of difficulty urinating and statistics the number of participants who developed these symptoms

    Time frame: 100 days after transplantation

  20. Number of participants who fell difficulty urinating at certain checkpoint of transplantation

    Use the Clinical Study Case Reports sheet to record whether each participant developed symptoms of difficulty urinating and statistics the number of participants who developed these symptoms

    Time frame: 180 days after transplantation

  21. Number of participants who fell difficulty urinating at certain checkpoint of transplantation

    Use the Clinical Study Case Reports sheet to record whether each participant developed symptoms of difficulty urinating and statistics the number of participants who developed these symptoms

    Time frame: 360 days before transplantation

  22. Number of participants who fell lethargy at certain checkpoint of transplantation

    Use the Clinical Study Case Reports sheet to record whether each participant developed symptoms of lethargy and statistics the number of participants who developed these symptoms

    Time frame: 5 days before transplantation

  23. Number of participants who fell lethargy at certain checkpoint of transplantation

    Use the Clinical Study Case Reports sheet to record whether each participant developed symptoms of lethargy and statistics the number of participants who developed these symptoms

    Time frame: 6 days after transplantation

  24. Number of participants who fell lethargy at certain checkpoint of transplantation

    Use the Clinical Study Case Reports sheet to record whether each participant developed symptoms of lethargy and statistics the number of participants who developed these symptoms

    Time frame: 30 days after transplantation

  25. Number of participants who fell lethargy at certain checkpoint of transplantation

    Use the Clinical Study Case Reports sheet to record whether each participant developed symptoms of lethargy and statistics the number of participants who developed these symptoms

    Time frame: 60 days after transplantation

  26. Number of participants who fell lethargy at certain checkpoint of transplantation

    Use the Clinical Study Case Reports sheet to record whether each participant developed symptoms of lethargy and statistics the number of participants who developed these symptoms

    Time frame: 100 days after transplantation

  27. Number of participants who fell lethargy at certain checkpoint of transplantation

    Use the Clinical Study Case Reports sheet to record whether each participant developed symptoms of lethargy and statistics the number of participants who developed these symptoms

    Time frame: 180 days after transplantation

  28. Number of participants who fell lethargy at certain checkpoint of transplantation

    Use the Clinical Study Case Reports sheet to record whether each participant developed symptoms of lethargy and statistics the number of participants who developed these symptoms

    Time frame: 360 days after transplantation

  29. Number of participants who fell dizziness, difficulty breathing, biliary colic, headache, stomachache, or anorexia at certain checkpoint of transplantation

    Use the Clinical Study Case Reports sheet to record whether each participant developed symptoms of dizziness, difficulty breathing, biliary colic, headache, stomachache, or anorexia and statistics the number of participants who developed these symptoms

    Time frame: 5 days before transplantation

  30. Number of participants who fell dizziness, difficulty breathing, biliary colic, headache, stomachache, or anorexia at certain checkpoint of transplantation

    Use the Clinical Study Case Reports sheet to record whether each participant developed symptoms of dizziness, difficulty breathing, biliary colic, headache, stomachache, or anorexia and statistics the number of participants who developed these symptoms

    Time frame: 6 days after transplantation

  31. Number of participants who fell dizziness, difficulty breathing, biliary colic, headache, stomachache, or anorexia at certain checkpoint of transplantation

    Use the Clinical Study Case Reports sheet to record whether each participant developed symptoms of dizziness, difficulty breathing, biliary colic, headache, stomachache, or anorexia and statistics the number of participants who developed these symptoms

    Time frame: 30 days after transplantation

  32. Number of participants who fell dizziness, difficulty breathing, biliary colic, headache, stomachache, or anorexia at certain checkpoint of transplantation

    Use the Clinical Study Case Reports sheet to record whether each participant developed symptoms of dizziness, difficulty breathing, biliary colic, headache, stomachache, or anorexia and statistics the number of participants who developed these symptoms

    Time frame: 60 days after transplantation

  33. Number of participants who fell dizziness, difficulty breathing, biliary colic, headache, stomachache, or anorexia at certain checkpoint of transplantation

    Use the Clinical Study Case Reports sheet to record whether each participant developed symptoms of dizziness, difficulty breathing, biliary colic, headache, stomachache, or anorexia and statistics the number of participants who developed these symptoms

    Time frame: 100 days after transplantation

  34. Number of participants who fell dizziness, difficulty breathing, biliary colic, headache, stomachache, or anorexia at certain checkpoint of transplantation

    Use the Clinical Study Case Reports sheet to record whether each participant developed symptoms of dizziness, difficulty breathing, biliary colic, headache, stomachache, or anorexia and statistics the number of participants who developed these symptoms

    Time frame: 180 days after transplantation

  35. Number of participants who fell dizziness, difficulty breathing, biliary colic, headache, stomachache, or anorexia at certain checkpoint of transplantation

    Use the Clinical Study Case Reports sheet to record whether each participant developed symptoms of dizziness, difficulty breathing, biliary colic, headache, stomachache, or anorexia and statistics the number of participants who developed these symptoms

    Time frame: 360 days after transplantation

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Oct 21, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05590091
Lead sponsor
Hebei Yanda Ludaopei Hospital
Responsible party
Sponsor
First posted
Oct 21, 2022
Start date
Nov 1, 2022 (estimated)
Primary completion
Mar 31, 2024 (estimated)
Completion
Mar 31, 2024 (estimated)
Last update
Oct 21, 2022

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Oct 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Other studies from this sponsor

Hebei Yanda Ludaopei Hospital

Start the discussion